Beyond inflammation: exploring CAR-based cell therapy for fibrostenosing Crohn’s disease
Open Access
- 30 October 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1967353
Abstract
Fibrostenosing Crohn’s disease (FSCD) is driven by chronic inflammation, fibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling. Current management includes medical treatment to control inflammation, endoscopic interventions, and surgery to relieve clinically significant strictures. Chimeric antigen receptor (CAR)-based cell therapy represents an emerging research direction that may enable targeted intervention against selected cell populations implicated in fibrogenesis. Unlike approaches focused primarily on inflammatory control, CAR-based strategies can be engineered to recognize selected cellular populations, offering a potential means of directly targeting cells involved in fibrotic remodeling or modulating the local profibrotic microenvironment. By integrating insights from intestinal pathobiology with evidence from other fibrotic settings, we assess candidate cellular targets, therapeutic modalities, and CAR-cell platforms, and consider how these choices should be aligned with lesion accessibility, disease stage, therapeutic objectives, and safety requirements. We further discuss the translational challenges of CAR-based approaches for FSCD.Keywords
This publication has 157 references indexed in Scilit:
- Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid TumorsAdvanced Materials, 2026
- CCR2/CXCR6 enhances tumor infiltration and antitumor efficacy of MSLN CAR-T cellsCellular and Molecular Life Sciences, 2025
- CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectivesCell Biochemistry and Function, 2024
- Comparative analysis of [18F]F-FAPI PET/CT, [18F]F-FDG PET/CT and magnetization transfer MR imaging to detect intestinal fibrosis in Crohn’s disease: A prospective animal model and human cohort studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Effects of B Cell Depletion by CD19‐Targeted Chimeric Antigen Receptor T Cells in a Murine Model of Systemic SclerosisArthritis & Rheumatology, 2023
- Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevanceImmunologic Research, 2022
- Controversial Contribution of Th17/IL-17 Toward the Immune Response in Intestinal FibrosisDigestive Diseases and Sciences, 2020
- Epithelial to Mesenchymal Transition (EMT) and Endothelial to Mesenchymal Transition (EndMT): Role and Implications in Kidney Fibrosis2017
- Alphavbeta6 is required in maintaining the intestinal epithelial barrier functionCell Biology International, 2014
- Monocyte chemoattractant protein-1 in idiopathic pulmonary fibrosis and other interstitial lung diseasesHuman Pathology, 1994